| Series |
Current topics in behavioral neurosciences, 1866-3370 ; volume 36 |
|
Current topics in behavioral neurosciences ;
36.
1866-3370
|
| Subject |
Hallucinogenic drugs.
|
|
Neurobiology.
|
|
Clinical neuropsychology.
|
|
Hallucinogens.
|
|
Brain -- drug effects.
|
|
Delusions -- chemically induced.
|
|
Neurobehavioral Manifestations -- drug effects.
|
| Alt Name |
Halberstadt, Adam L.,
|
|
Vollenweider, Franz X.,
|
|
Nichols, David E., 1944-
|
| Description |
1 online resource (x, 430 pages) : illustrations (some color). |
|
polychrome rdacc |
| Contents |
Intro; Preface; References; Contents; 475 Chemistry and Structure-Activity Relationships of Psychedelics; Abstract; 1 Introduction; 2 Tryptamines; 2.1 Ring Substituents; 2.2 N-Alkylation; 2.3 Side Chain Alkylation; 3 Ergolines; 3.1 Amide Modifications of Lysergic Acid Derivatives; 3.2 N(6)-Alkyl Modifications of LSD; 4 Ergolines as "Research Chemicals"; 5 Phenethylamines and Related Congeners; 5.1 Beta-Oxygenated Phenethylamines; 5.2 Ring Substituents; 5.3 Methoxy Mimics-Benzofuran and Benzopyran Analogues; 5.4 Effect of Side Chain Alpha-Alkylation. |
|
6 Identifying the "Active" Conformation of the Phenethylamines6.1 Effect of an N-Benzyl Group; 6.2 The Active Conformation of N-Benzylphenethylamines; 7 Modeling the Receptor-Ligand Interaction; 8 Conclusion; References; 478 Hallucinogens and Serotonin 5-HT2A Receptor-Mediated Signaling Pathways; Abstract; 1 Introduction to Receptor Pharmacology; 2 Serotonin and Serotonin Receptors: A Historical Perspective; 2.1 Serotonin; 2.2 Serotonin Receptors; 3 Chemical Neuroanatomy of 5-HT2A Receptors; 4 Hallucinogenic and Non-Hallucinogenic 5-HT2A Receptor Agonists. |
|
5 Biased Agonism at the 5-HT2A Receptor6 Additional Signaling Pathways Modulated by Activation of the 5-HT2A Receptor; 7 Role of mGlu2 Receptor in Hallucinogen Action; 8 Future Directions; Acknowledgements; References; 473 Effects of Hallucinogens on Neuronal Activity; Abstract; 1 Hallucinogens as Pharmacological Models in Schizophrenia Research; 1.1 Serotonergic Hallucinogens; 1.2 NMDA Receptors. Noncompetitive Antagonists; 2 The Prefrontal Cortex; 3 Effects of Psychotomimetic Agents on Neuronal Activity in PFC; 3.1 Serotonergic Hallucinogens; 3.2 Noncompetitive NMDA Receptor Antagonists. |
|
4 Role of Thalamocortical Inputs5 Brain Oscillations: Relevance to Schizophrenia; 6 Effects of Psychotomimetic Agents on Low Frequency Cortical Oscillations; 7 Mechanisms Involved in the Reversal by Antipsychotic Drugs; 8 Concluding Remarks; Acknowledgements; References; 480 Interactions of Hallucinogens with the Glutamatergic System: Permissive Network Effects Mediated Through Cortical Layer V Pyramidal Neurons; Abstract; 1 From 5-HT2A Receptor-Induced EPSCs and Recurrent Neuronal Activity to Salient Behavioral Effects Induced by 5-HT2A Receptor Activation. |
|
2 Clinical Relevance of the Interactions Between Glutamate and 5-HT2A Receptors in the mPFC3 Conclusions; References; 479 The Effects of Hallucinogens on Gene Expression; Abstract; 1 Introduction; 2 Immediate Early Genes; 3 IEG and 5-HT2A Receptor Expression: Early Studies; 4 Identification of Tissues that Transcriptionally Respond to Psychedelics: Early Studies; 5 IEG and 5-HT2A Receptor Expression in the Post-Genomic Era; 6 Psychedelics, Gene Expression, and Cellular Signaling; 7 Identification and Characterization of the Cortical Cellular Population Responsive to Psychedelics. |
| Summary |
This volume brings together the latest basic and clinical research examining the effects and underlying mechanisms of psychedelic drugs. Examples of drugs within this group include LSD, psilocybin, and mescaline. Despite their structural differences, these compounds produce remarkably similar experiences in humans and share a common mechanism of action. Commonalities among the substances in this family are addressed both at the clinical and phenomenological level and at the basic neurobiological mechanism level. To the extent possible, contributions relate the clinical and preclinical findings to one another across species. The volume addresses both the risks associated with the use of these drugs and the potential medical benefits that might be associated with these and related compounds. |
| Note |
Online resource; title from PDF title page (SpringerLink, viewed April 3, 2018). |
| ISBN |
9783662558805 (electronic bk.) |
|
3662558807 (electronic bk.) |
|
9783662558782 (print) |
|
3662558785 |
| ISBN/ISSN |
10.1007/978-3-662-55880-5 |
| OCLC # |
1030302735 |
| Additional Format |
Print version: 3662558785 9783662558782 (DLC) 2018931899 (OCoLC)1002015742 |
|
Search 
Search 
Previous Item
Permanent Link
